ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Upregulation of WDR4 mediated by RBFOX2 promotes laryngeal cancer progression through the WDR4/m7G/lncRNA ZFAS1/RBFOX2 axis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High expression of STAT3 and PD-L1 predicts poor prognosis for laryngeal squamous cell carcinoma.Scientific reports · 2026Article
- Epitranscriptomic control of epithelial-mesenchymal transition in cancer: mechanisms, plasticity, and therapeutic opportunities.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High levels of the N7 methylguanosine (m7G) methyltransferase WD repeat domain 4 (WDR4) are associated with the progression of multiple tumors, including head and neck squamous cell carcinoma. Laryngeal cancer (LC) is the second most common malignant tumor of the head and neck. However, the role of WDR4 in LC remains unclear. Here, we found that WDR4 expression was significantly upregulated in LC tissues and cells. Silencing WDR4 inhibited proliferation, invasion, and epithelial-mesenchymal transition (EMT, manifested by an increase in E-cadherin protein levels and a decrease in N-cadherin and Vimentin protein levels) in TU177 and M4E cells. Furthermore, the levels of m7G and ZFAS1 were significantly upregulated in LC tissues and cells. Mechanistic studies revealed that WDR4 upregulated the levels of ZFAS1 and RBFOX2 proteins by promoting the stability of ZFAS1 in an m7G-dependent manner, and RBFOX2 promoted WDR4 expression by binding to WDR4 mRNA. Overexpression of WDR4 increased m7G and ZFAS1 levels, whereas overexpression of WDR4 with m7G catalytic site mutation had no effect on m7G and ZFAS1 levels in TU177 and M4E cells. Silencing ZFAS1 or RBFOX2 counteracted the promoting effect of WDR4 overexpression on the malignant proliferation of TU177 and M4E cells. TU177 cells transfected with sh-WDR4 lentiviral vectors were intraperitoneally injected into nude mice to construct xenograft tumor models. Knockdown of WDR4 significantly inhibited LC tumor growth in vivo. In conclusion, RBFOX2-mediated upregulation of WDR4 promoted LC progression through the WDR4/m7G/ZFAS1/RBFOX2 axis.
Indexed as
Identifiers
39774908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.